EraGen and Illumina Enter Cross-Licensing Deal for Molecular Diagnostics

EraGen Biosciences and Illumina are combining technologies to advance molecular diagnostic offerings. EraGen Biosciences will have access to Illumina’s BeadXpress platform for the development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its own MultiCode®-PLx technology. Illumina has licensed EraGen’s MultiCode-PLx platform for the life sciences, research, and clinical markets.